REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31

Replimune Group, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$11.05+0.19 (+1.75%)

Close on Oct 19, 2026

Market cap: $1.07B
P/E (TTM): –
Dividend yield: –

Replimune Group, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q1 2027 2026-06-30	Q4 2026 2026-03-31	Q3 2026 2025-12-31	Q2 2026 2025-09-30	Q1 2026 2025-06-30	Q4 2025 2025-03-31	Q3 2025 2024-12-31	Q2 2025 2024-09-30	Q1 2025 2024-06-30	Q4 2024 2024-03-31	Q3 2024 2023-12-31	Q2 2024 2023-09-30	Q1 2024 2023-06-30	Q4 2023 2023-03-31	Q3 2023 2022-12-31	Q2 2023 2022-09-30	Q1 2023 2022-06-30	Q4 2022 2022-03-31	Q3 2022 2021-12-31	Q2 2022 2021-09-30	Q1 2022 2021-06-30	Q4 2021 2021-03-31	Q3 2021 2020-12-31	Q2 2021 2020-09-30	Q1 2021 2020-06-30	Q4 2020 2020-03-31	Q3 2020 2019-12-31	Q2 2020 2019-09-30	Q1 2020 2019-06-30	Q4 2019 2019-03-31	Q3 2019 2018-12-31	Q2 2019 2018-09-30	Q1 2019 2018-06-30	Q4 2018 2018-03-31	Q3 2018 2017-12-31	Q2 2018 2017-09-30	Q1 2018 2017-06-30
Depreciation & Amortization	0.94	0.77	0.80	0.80	0.87	0.85	1.00	0.90	0.74	0.71	0.70	0.70	0.62	0.53	0.68	0.62	0.62	0.55	0.55	0.53	0.52	0.49	0.40	0.43	0.39	0.34	0.11	0.04	0.04	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.02
Stock-Based Compensation	7.67	8.13	7.05	8.34	8.76	8.28	8.64	8.65	9.48	7.92	8.24	9.11	8.85	6.92	7.02	6.99	7.19	5.77	5.92	6.31	6.25	3.47	3.05	2.80	2.47	1.81	2.34	1.78	1.81	0.91	0.88	0.72	0.23	0.35	0.26	0.16	0.05
Change in Accounts Payable	-2.33	0.96	-0.73	-8.93	3.77	5.24	-1.15	7.46	-1.62	-1.29	-0.48	-0.21	-0.82	1.62	-0.34	-0.20	0.90	-0.08	0.44	0.68	0.07	-0.01	0.18	-0.97	-0.22	-1.24	-1.69	-4.66	3.76	0.64	-0.67	0.41	-0.26	1.42	-0.40	0.20	0.38
Operating Cash Flow	-76	-56	-66	-81	-77	-54	-51	-39	-49	-46	-47	-44	-49	-33	-29	-33	-33	-23	-18	-23	-18	-16	-13	-17	-15	-11	-16	-20	-14	-6.03	-6.10	-6.38	-6.86	-4.23	-2.70	-3.59	-5.49
Capital Expenditures	-0.01	-0.01	-0.14	-1.34	-2.74	-1.13	-1.80	-2.08	-1.67	-1.74	-1.72	-1.75	-0.45	-0.25	-0.56	-0.40	-1.07	-1.15	-0.47	-0.43	-0.29	-0.77	-0.62	-0.08	-0.93	-1.34	-4.06	-0.78	-0.36	-1.85	-0.63	0.00	-0.12	0.00	-0.01	-0.10	-0.03
Purchase of Investments	-9.88	-3.95	-27	-9.85	-38	-72	-137	-89	-105	-108	-100	-112	-169	-150	-240	-133	-61	-63	-81	-79	-32	-167	-28	-71	-126	-30	-89	-12	-18	-55	-24	-100	-11	-27	–	–	–
Investing Cash Flow	50	87	75	84	65	-7.70	-46	0.46	30	23	54	13	7.36	-23	-125	0.04	5.32	-4.33	-13	-11	27	-126	31	-45	-49	7.84	-65	25	27	10	3.80	-85	4.89	-18	-26	-0.10	-0.03
Stock Issued	–	–	–	0	0	0.00	108	0	48	0	0	0	0	-0.25	6.70	6.70	31	0	0	0	0	0	211	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Debt Issued	–	–	–	–	–	0	–	–	–	0	–	–	–	-1.85	–	–	–	0	–	–	–	–	–	–	–	0	0	–	–	–	–	–	–	–	–	–	–
Debt Repaid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	0.80	56	10	0.32	-0.16	-0.13	156	-0.04	97	-0.13	15	0.44	1.11	-0.08	271	7.42	33	0.36	3.97	1.15	1.12	0.79	262	-0.04	110	0.03	90	9.75	0.02	0.04	0.15	101	-0.20	0	0	–	–
Foreign Exchange Rate Adjustments	1.27	0.05	1.04	1.64	-1.62	0.44	-0.15	0.06	-0.04	-0.06	-0.03	-0.02	0.01	-4.45	-0.01	2.44	1.92	0.20	0.11	0.30	0.21	-0.34	0.52	0.54	0.00	-0.12	0.28	-0.17	-0.14	0.17	-0.08	-0.20	-0.73	0.69	–	–	–
Net Change in Cash	-24	86	21	4.92	-14	-61	59	-38	77	-23	22	-30	-40	-60	118	-23	6.30	-26	-28	-33	10	-142	281	-61	45	-3.50	9.70	15	13	4.65	-2.23	9.70	-2.90	-22	-28	52	-4.63
Free Cash Flow	-76	-56	-66	-83	-80	-55	-53	-41	-51	-48	-49	-45	-49	-33	-29	-34	-35	-24	-19	-23	-19	-17	-14	-17	-16	-13	-20	-21	-14	-7.88	-6.74	-6.39	-6.98	-4.23	-2.70	-3.69	-5.53
Income Taxes Paid	0.03	-0.13	–	–	0	0	0.11	–	–	0	0	–	–	0	0	–	–	0	0.01	–	–	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	1.78	1.51	1.04	1.08	1.06	1.04	0.29	1.81	1.05	1.01	0.69	0.69	0.65	1.07	0	0	0	0	0	0	0	0	0.19	0.22	0.22	0.30	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -107.9%

Financial strength

Current ratio: 5.23
Debt to equity: 0.80
Debt to assets: 33.3%
Cash to current liabilities: 482.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 10.13
Dividend yield: –